We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+22.79%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$986M
AUM Growth
+$157M
Cap. Flow
+$52.5M
Cap. Flow %
5.32%
Top 10 Hldgs %
59.81%
Holding
50
New
8
Increased
8
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$82.5M
2
MRUS
Merus
MRUS
+$43.9M
3
XNCR icon
Xencor
XNCR
+$23.6M
4
RCUS icon
Arcus Biosciences
RCUS
+$21.2M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$14.1M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$58M
2
CTMX icon
CytomX Therapeutics
CTMX
+$23.7M
3
ANAB icon
AnaptysBio
ANAB
+$23.5M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$11.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 83.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
1
DELISTED
ChemoCentryx, Inc.
CCXI
$97.9M 9.93%
7,201,316
-386,100
-5% -$3.98M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$686M
$85.5M 8.67%
+6,617,626
New +$82.5M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$82.6M 8.38%
5,062,768
-3,623,730
-42% -$58M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$60.1M 6.09%
655,611
-111,743
-15% -$9.63M
ARQL
5
DELISTED
Arqule Inc
ARQL
$47.3M 4.8%
16,436,912
– –
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.67B
$46M 4.66%
3,233,618
– –
MRUS
7
DELISTED
Merus
MRUS
$44.8M 4.54%
+2,419,443
New +$43.9M
CNCE
8
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$44.2M 4.49%
1,932,123
-37,666
-2% -$838K
CYTK icon
9
Cytokinetics
CYTK
$10.6B
$41.2M 4.18%
5,721,888
– –
ANAB icon
10
AnaptysBio
ANAB
$1.57B
$40.2M 4.07%
386,065
-208,332
-35% -$23.5M
XOMA
11
DELISTED
Xoma
XOMA
$30.4M 3.08%
1,502,800
– –
XNCR icon
12
Xencor
XNCR
$1.5B
$27M 2.74%
+902,000
New +$23.6M
CTIC
13
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$27M 2.74%
6,929,690
-1,666,667
-19% -$5.86M
KURA icon
14
Kura Oncology
KURA
$793M
$25.4M 2.57%
1,353,846
– –
PVLA
15
Palvella Therapeutics
PVLA
$2.04B
$24.5M 2.48%
44,907
+12,112
+37% +$7.5M
BLRX
16
BioLineRX
BLRX
$12M
$22.6M 2.29%
43,326
– –
CRVS icon
17
Corvus Pharmaceuticals
CRVS
$1.1B
$22.5M 2.28%
1,954,254
+1,494,858
+325% +$14.1M
INFI
18
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$20.5M 2.08%
9,766,508
– –
RCUS icon
19
Arcus Biosciences
RCUS
$3.48B
$19.6M 1.99%
+1,269,788
New +$21.2M
SPRO icon
20
Spero Therapeutics
SPRO
$68.3M
$14.9M 1.52%
1,048,958
+19,773
+2% +$240K
IMDZ
21
DELISTED
Immune Design Corp.
IMDZ
$13.6M 1.37%
4,106,200
+2,636,400
+179% +$9.33M
OMED
22
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$13.5M 1.37%
4,253,189
-18,100
-0.4% -$49.9K
PHXM
23
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$13.1M 1.33%
62,500
– –
FSTX
24
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$12.8M 1.3%
208,062
+2,193
+1% +$116K
VBIV
25
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$10.8M 1.1%
103,333
– –
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2018 Portfolio in Review

As of Q1 2018, BVF Inc held 50 positions worth $986M, up 19% from $830M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

BVF Inc deployed $52.5M of net new capital in Q1 2018, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Ironwood Pharmaceuticals: 6,617,626 shares worth $85.5M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $58M trimmed.

  • BVF Inc's largest Q1 2018 buy was Ironwood Pharmaceuticals: 6,617,626 shares worth $85.5M.
  • BVF Inc added most to Corvus Pharmaceuticals in Q1 2018, an estimated $14.1M increase.
  • BVF Inc's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $58M.
  • BVF Inc fully exited CytomX Therapeutics in Q1 2018, selling an estimated $23.7M.
  • BVF Inc's ten largest holdings make up 60% of its $986M portfolio in Q1 2018.
  • BVF Inc opened 8 new positions and closed 7 in Q1 2018.
  • BVF Inc's portfolio value rose 19% quarter-over-quarter to $986M.

Based on BVF Inc's 13F filing for Q1 2018, filed 7 May 2018.